These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 17288540)

  • 1. Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays.
    Baillie GS; Adams DR; Bhari N; Houslay TM; Vadrevu S; Meng D; Li X; Dunlop A; Milligan G; Bolger GB; Klussmann E; Houslay MD
    Biochem J; 2007 May; 404(1):71-80. PubMed ID: 17288540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Scanning peptide array analyses identify overlapping binding sites for the signalling scaffold proteins, beta-arrestin and RACK1, in cAMP-specific phosphodiesterase PDE4D5.
    Bolger GB; Baillie GS; Li X; Lynch MJ; Herzyk P; Mohamed A; Mitchell LH; McCahill A; Hundsrucker C; Klussmann E; Adams DR; Houslay MD
    Biochem J; 2006 Aug; 398(1):23-36. PubMed ID: 16689683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells.
    Lynch MJ; Baillie GS; Mohamed A; Li X; Maisonneuve C; Klussmann E; van Heeke G; Houslay MD
    J Biol Chem; 2005 Sep; 280(39):33178-89. PubMed ID: 16030021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Arrestin-mediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi.
    Baillie GS; Sood A; McPhee I; Gall I; Perry SJ; Lefkowitz RJ; Houslay MD
    Proc Natl Acad Sci U S A; 2003 Feb; 100(3):940-5. PubMed ID: 12552097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 1H NMR structural and functional characterisation of a cAMP-specific phosphodiesterase-4D5 (PDE4D5) N-terminal region peptide that disrupts PDE4D5 interaction with the signalling scaffold proteins, beta-arrestin and RACK1.
    Smith KJ; Baillie GS; Hyde EI; Li X; Houslay TM; McCahill A; Dunlop AJ; Bolger GB; Klussmann E; Adams DR; Houslay MD
    Cell Signal; 2007 Dec; 19(12):2612-24. PubMed ID: 17900862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5.
    Li X; Baillie GS; Houslay MD
    J Biol Chem; 2009 Jun; 284(24):16170-16182. PubMed ID: 19372219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The unique amino-terminal region of the PDE4D5 cAMP phosphodiesterase isoform confers preferential interaction with beta-arrestins.
    Bolger GB; McCahill A; Huston E; Cheung YF; McSorley T; Baillie GS; Houslay MD
    J Biol Chem; 2003 Dec; 278(49):49230-8. PubMed ID: 14500724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-arrestin-recruited phosphodiesterase-4 desensitizes the AKAP79/PKA-mediated switching of beta2-adrenoceptor signalling to activation of ERK.
    Houslay MD; Baillie GS
    Biochem Soc Trans; 2005 Dec; 33(Pt 6):1333-6. PubMed ID: 16246112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cAMP-specific phosphodiesterase-4D5 (PDE4D5) provides a paradigm for understanding the unique non-redundant roles that PDE4 isoforms play in shaping compartmentalized cAMP cell signalling.
    Lynch MJ; Baillie GS; Houslay MD
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):938-41. PubMed ID: 17956250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells. Identification and characterization of a novel PDE4D5 promoter.
    Le Jeune IR; Shepherd M; Van Heeke G; Houslay MD; Hall IP
    J Biol Chem; 2002 Sep; 277(39):35980-9. PubMed ID: 12121997
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations of beta-arrestin 2 that limit self-association also interfere with interactions with the beta2-adrenoceptor and the ERK1/2 MAPKs: implications for beta2-adrenoceptor signalling via the ERK1/2 MAPKs.
    Xu TR; Baillie GS; Bhari N; Houslay TM; Pitt AM; Adams DR; Kolch W; Houslay MD; Milligan G
    Biochem J; 2008 Jul; 413(1):51-60. PubMed ID: 18435604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK).
    Baillie G; MacKenzie SJ; Houslay MD
    Mol Pharmacol; 2001 Nov; 60(5):1100-11. PubMed ID: 11641439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions.
    Beard MB; Olsen AE; Jones RE; Erdogan S; Houslay MD; Bolger GB
    J Biol Chem; 2000 Apr; 275(14):10349-58. PubMed ID: 10744723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the G protein-coupled receptor kinase site serine cluster in beta2-adrenergic receptor internalization, desensitization, and beta-arrestin translocation.
    Vaughan DJ; Millman EE; Godines V; Friedman J; Tran TM; Dai W; Knoll BJ; Clark RB; Moore RH
    J Biol Chem; 2006 Mar; 281(11):7684-92. PubMed ID: 16407241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineation of RAID1, the RACK1 interaction domain located within the unique N-terminal region of the cAMP-specific phosphodiesterase, PDE4D5.
    Bolger GB; McCahill A; Yarwood SJ; Steele MR; Warwicker J; Houslay MD
    BMC Biochem; 2002 Aug; 3():24. PubMed ID: 12193273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at Ser239 and Ser579.
    Hill EV; Sheppard CL; Cheung YF; Gall I; Krause E; Houslay MD
    Cell Signal; 2006 Nov; 18(11):2056-69. PubMed ID: 16973330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ndel1 alters its conformation by sequestering cAMP-specific phosphodiesterase-4D3 (PDE4D3) in a manner that is dynamically regulated through Protein Kinase A (PKA).
    Collins DM; Murdoch H; Dunlop AJ; Charych E; Baillie GS; Wang Q; Herberg FW; Brandon N; Prinz A; Houslay MD
    Cell Signal; 2008 Dec; 20(12):2356-69. PubMed ID: 18845247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The RACK1 signaling scaffold protein selectively interacts with the cAMP-specific phosphodiesterase PDE4D5 isoform.
    Yarwood SJ; Steele MR; Scotland G; Houslay MD; Bolger GB
    J Biol Chem; 1999 May; 274(21):14909-17. PubMed ID: 10329691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RACK1 and β-arrestin2 attenuate dimerization of PDE4 cAMP phosphodiesterase PDE4D5.
    Bolger GB
    Cell Signal; 2016 Jul; 28(7):706-12. PubMed ID: 26257302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dimerization of cAMP phosphodiesterase-4 (PDE4) in living cells requires interfaces located in both the UCR1 and catalytic unit domains.
    Bolger GB; Dunlop AJ; Meng D; Day JP; Klussmann E; Baillie GS; Adams DR; Houslay MD
    Cell Signal; 2015 Apr; 27(4):756-69. PubMed ID: 25546709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.